<DOC>
	<DOCNO>NCT00432016</DOCNO>
	<brief_summary>The purpose study determine short term safety , tolerance , antiviral effect zidovudine ( AZT ) amdoxovir ( AMDX , DAPD ) combination , whether dosage AZT reduce , potentially decrease side effect , maintain antiviral effect . Study hypothesis : DADP combination AZT safe effective , AZT dosing may reduce , result low level AZT-monophosphate associate toxicity maintaining level AZT-triphosphate associate efficacy .</brief_summary>
	<brief_title>Safety , Tolerance , Pharmacokinetic Antiviral Study Amdoxovir Combination With Zidovudine Adults With HIV</brief_title>
	<detailed_description>By 2008 , market data suggest commonly prescribed initial treatment regimen HIV-1 consist Truvada® ( FTC tenofovir disoproxil fumarate ( TDF ) ) Sustiva® ( efavirenz ( EFV ) ) . A newly formulate drug call Atripla™ contain three active ingredient approve US FDA . Therefore , second line treatment currently development provide activity resultant mutation , primarily M184V/I ( 17 % ) much less commonly K65R ( 0 5 % ) , ideally prevent effective mutation may occur second line therapy . The goal program identify AZT/DAPD co-formulation reduce resistance development improve safety profile treatment HIV infection . DAPD increase sensitivity M184V/I strain active thymidine analog mutation ( TAMs ) may occur previous antiretroviral regimen . AZT offer anti-K65R activity believe confer 3'-azido moiety contain pseudo-sugar structure base component AZT . Hence , AZT could potentially incorporate prevent emergence K65R mutation could limit long-term benefit DAPD . Since nucleoside reverse transcriptase inhibitor ( NRTIs ) require intracellular phosphorylation form active triphosphates , preferable combine NRTIs different critical kinase . Thymidine kinase-1 critical enzyme phosphorylation AZT monophosphates . The enzyme involve initial phosphorylation active metabolite DAPD , DXG , guanosine kinase . Nucleotide competition study conduct use activate human peripheral blood mononuclear ( PBM ) cell perform DAPD AZT concentration 0.1-10 µM demonstrate competitive inhibition DXG-triphosphate formation . The approved dose AZT 300 mg bid , AZT available 300 mg tablet 100 mg capsule . A previous study 10 HIV seropositive individual compare cellular AZT-mono , di- tri-phosphate nucleotide normal reduced dos , 100 mg tid versus 300 mg bid , demonstrate significant decrease plasma AZT intracellular AZT-monophosphate ( AZT-MP ) level , ( AZT-MP associate toxicity ) , without significant change AZT-triphosphate ( AZT-TP ) level activate PBM cell antiviral activity . These finding effect AZT dose intracellular AZT-TP support computer simulation . Maximal predict cellular level AZT-MP AZT-TP steady-state , follow 200 mg bid 300 mg bid dose 3,000 simulated individual demonstrate high overlap AZT-TP histogram ( &gt; 85 % ) , suggest similar efficacy 200 300 mg bid dose . The low degree overlap AZT-MP histogram ( &lt; 8 % ) two dose regimen , suggest may fewer toxicity 200 mg bid dose , support hypothesis zidovudine dose 200 mg bid could reduce AZT-MP level without compromise AZT-TP level would obtain 300 mg bid dose . This 10 day , proof principle , pharmacokinetic study provide important information reduce AZT dose support development AZT/DAPD co-formulation may prevent emergence K65R mutation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>HIVinfection Antiretroviral therapy naïve , experience , treatment within 90 day study screen plan remain therapy duration screen study treatment period HIV1 RNA ≥ 5,000 copies/mL within 30 day study Day 1 CD4+ count ≥ 200 cells/mm³ within 30 day study Day 1 Agree use two form adequate contraception woman , one form men Estimated creatinine clearance &gt; 80 mL/min Serum creatinine &lt; 1.5 g/dL Able give write informed consent prior study start adhere study requirement Active alcohol drug use opinion Investigator likely compromise adherence study requirement A positive urine test amphetamine , cocaine , and/or opioids Currently active AIDS defining illness ( Category C condition accord CDC Classification System HIV Infection 1993 ) Any active clinically significant disease finding screen medical history physical examination Investigator ’ opinion would compromise outcome study Receiving oral concomitant antiviral prophylactic drug opportunistic infection within 30 day prior study entry Receiving concomitant treatment nephrotoxic drug ( e.g. , aminoglycosides [ tobramycin , gentamicin , amikacin ] , amphotericin B , vancomycin , cidofovir , foscarnet , cisplatinum , pentamidine ) , competitor renal excretion ( e.g. , probenecid ) within 30 day study entry Visual abnormality ( e.g . cataract , macular degeneration ) nonorganic decrease visual acuity Receiving concomitant treatment immunosuppressive drug within 30 day prior study entry Diabetes mellitus Type 1 2 treated antidiabetes agent Current significant gastrointestinal , renal , hepatic , bronchopulmonary , biliary , neurological , cardiovascular , oncologic , allergic , ophthalmologic disease include history cataracts/lens opacities The following laboratory value perform within 30 day prior study Day 1 : Hemoglobin &lt; 9.0 g/dL men ; 8.0 g/dL woman Platelet count &lt; 75,000 cell per mL Absolute neutrophil count &lt; 1,000 cell per mL AST , ALT , alkaline phosphatase , amylase &gt; 3 x ULN Random fast glucose &gt; 121 mg/dL Serum lipase &gt; 1.5 x ULN Urinalysis ≥ 2+ proteinuria ≥ 2 cellular cast per high power field ( HPF ) Active acute hepatitis A and/or chronic hepatitis B C detectable viremia Subjects clinical laboratory evidence significantly decrease hepatic function decompensation , irrespective liver enzyme level ( INR &gt; 1.3 albumin &lt; 30 g/l bilirubin &gt; 2.5 x ULN ) Pregnant woman Breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>zidovudine</keyword>
	<keyword>amdoxovir</keyword>
	<keyword>DAPD</keyword>
	<keyword>AMDX</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>